We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$193M
AUM Growth
-$17.7M
Cap. Flow
+$46.7M
Cap. Flow %
24.24%
Top 10 Hldgs %
52.19%
Holding
80
New
22
Increased
10
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$23.6M
2
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
+$9.19M
3
BIIB icon
Biogen
BIIB
+$4.6M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$3.86M
5
ZBH icon
Zimmer Biomet
ZBH
+$3.69M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$6.61M
2
TMO icon
Thermo Fisher Scientific
TMO
+$6.28M
3
HCA icon
HCA Healthcare
HCA
+$5.27M
4
PBYI icon
Puma Biotechnology
PBYI
+$4.91M
5
PHG icon
Philips
PHG
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 59.52%
2 Financials 4.17%
3 Technology 0.91%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OASM
51
DELISTED
Oasmia Pharmaceutical AB
OASM
$211K 0.11%
203,170
– –
CCXI
52
DELISTED
ChemoCentryx, Inc.
CCXI
$187K 0.1%
25,182
-219,668
-90% -$1.83M
STDY
53
DELISTED
SteadyMed Ltd
STDY
$184K 0.1%
54,950
-113,050
-67% -$601K
VIRX
54
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$65K 0.03%
963
– –
ABBV icon
55
PUT
AbbVie
ABBV
$471B
– –
-70,000
Closed -$5.08M
ACAD icon
56
PUT
Acadia Pharmaceuticals
ACAD
$4.44B
– –
-60,000
Closed -$1.67M
AXSM icon
57
Axsome Therapeutics
AXSM
$12B
– –
-160,000
Closed -$880K
HCA icon
58
HCA Healthcare
HCA
$92.2B
– –
-60,420
Closed -$5.27M
HCA icon
59
PUT
HCA Healthcare
HCA
$92.2B
– –
-30,000
Closed -$2.62M
JNJ icon
60
PUT
Johnson & Johnson
JNJ
$647B
– –
-70,000
Closed -$9.26M
LLY icon
61
Eli Lilly
LLY
$1.09T
– –
-33,473
Closed -$2.75M
LLY icon
62
PUT
Eli Lilly
LLY
$1.09T
– –
-40,000
Closed -$3.29M
MED icon
63
PUT
Medifast
MED
$108M
– –
-38,500
Closed -$1.6M
PEN icon
64
PUT
Penumbra
PEN
$12.6B
– –
-20,000
Closed -$1.75M
PHG icon
65
CALL
Philips
PHG
$24.9B
– –
-11,725
Closed -$319K
REGN icon
66
PUT
Regeneron Pharmaceuticals
REGN
$72.3B
– –
-7,000
Closed -$3.44M
RVTY icon
67
Revvity
RVTY
$12.5B
– –
-53,899
Closed -$3.67M
SNN icon
68
Smith & Nephew
SNN
$13.7B
– –
-77,244
Closed -$2.69M
TMO icon
69
Thermo Fisher Scientific
TMO
$213B
– –
-35,965
Closed -$6.28M
NVRO
70
DELISTED
NEVRO CORP.
NVRO
– –
-33,250
Closed -$2.48M
TRHC
71
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
– –
-312,630
Closed -$4.71M
ZYNE
72
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-70,300
Closed -$1.19M
VRAY
73
DELISTED
ViewRay, Inc.
VRAY
– –
-313,947
Closed -$2.03M
ACOR
74
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-3,167
Closed -$7.49M
CLVS
75
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-12,500
Closed -$1.17M
1 2
3
4

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sio Capital Management held 80 positions worth $193M, down 8.4% from $210M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Sio Capital Management deployed $46.7M of net new capital in Q3 2017, opening 22 new positions and adding to 10 existing holdings. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 51% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Sanofi, an estimated $6.61M trimmed.

  • Sio Capital Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.
  • Sio Capital Management added most to DMK Pharmaceuticals Corporation Common Stock in Q3 2017, an estimated $9.19M increase.
  • Sio Capital Management's biggest Q3 2017 reduction was Sanofi, cutting an estimated $6.61M.
  • Sio Capital Management fully exited Thermo Fisher Scientific in Q3 2017, selling an estimated $6.28M.
  • Sio Capital Management's ten largest holdings make up 52% of its $193M portfolio in Q3 2017.
  • Sio Capital Management opened 22 new positions and closed 26 in Q3 2017.
  • Sio Capital Management's portfolio value fell 8.4% quarter-over-quarter to $193M.

Based on Sio Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.